D.E. Shaw & Co’s Neuropace NPCE Stock Holding History

D.E. Shaw & Co’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Buy	161,081 +117,456	+269%	+$1.89M	﹤0.01%	2986
2026 Q1	$574K	Buy	+43,625	New	+$654K	﹤0.01%	3781

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

D.E. Shaw & Co's NPCE Position: Q2 2026 in Review

D.E. Shaw & Co increased its Neuropace (NPCE) stake by 269% in Q2 2026, buying an estimated $1.89M and bringing the position to 161,081 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2986.

D.E. Shaw & Co first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

D.E. Shaw & Co held 161,081 shares of Neuropace worth $2.56M as of Q2 2026.
D.E. Shaw & Co bought 117,456 Neuropace shares in Q2 2026, an estimated $1.89M.
Neuropace made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2986 holding.
D.E. Shaw & Co first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.